title: Validation of a flow cytometric acridine orange micronuclei methodology in rats.
abstract: Our laboratory has previously reported a flow cytometric acridine orange method for detection of micronucleus (MN) in the rat using cyclophosphamide as a test compound. To replace the manual method of scoring and satisfy Good Laboratory Practice (GLP) requirements, an extensive validation of the flow method was required. Therefore, manual scoring and flow cytometric determination of MN were compared using vincristine, chlorambucil, methotrexate, and doxorubicin compounds known to induce MN formation with various mechanisms of action. 1,2-Dimethylhydrazine (1,2-DH), a compound with negative or equivocal MN findings also was evaluated. The flow method consistently demonstrated dose- and time-dependent responses for MN production at all concentrations of vincristine, methotrexate, clorambucil, and doxorubicin. In contrast, manual scoring of slides failed to detect an increase in MN at the lowest doses of doxorubicin (1mg/kg) at 24 or 48 h, and methotrexate at 48 h, or any dose of methotrexate (50, 100, or 250 mg/kg) at 24h. Additionally, a dose-response for methotrexate at 48 h, and chlorambucil at 24 h were missed using manual scoring. For 1,2-DH, the flow method showed a low level (< 1.4-fold) increase in MN at all doses and times. In contrast, the manual method showed five-seven-fold increases at 24 h, but a < two-fold increase at 48 h in the highest dose only. These data may suggest that the flow method has a greater sensitivity and possibly accuracy than manual scoring. Significant decreases in polychromatic erythrocytes (PCE) were seen using both methods at approximately the same dose for all compounds. However, absolute flow cytometric PCE values were consistently higher than manual. Additional cytotoxicity parameters obtained by the flow method allowed a more complete assessment of cytotoxicity than PCE alone. Furthermore, data reported here combined with improved throughput, shortened data turnaround and reporting times, and possibly better precision due to evaluation of much larger numbers of cells clearly demonstrate the usefulness of flow cytometry method in the routine micronucleus evaluation.
authors.affiliation: Drug Safety Evaluation, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MI 48105, USA. kay.criswell@pfizer.com
authors.forename: K A
authors.initials: KA
authors.lastname: Criswell
authors.forename: G
authors.initials: G
authors.lastname: Krishna
authors.forename: D
authors.initials: D
authors.lastname: Zielinski
authors.forename: G A
authors.initials: GA
authors.lastname: Urda
authors.forename: P
authors.initials: P
authors.lastname: Juneau
authors.forename: S
authors.initials: S
authors.lastname: Bulera
authors.forename: M R
authors.initials: MR
authors.lastname: Bleavins
mesh_terms: D019813:1,2-Dimethylhydrazine / Q000633:toxicity; D000165:Acridine Orange; D000284:Administration, Oral; D000818:Animals; D002699:Chlorambucil / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity; D005434:Flow Cytometry; D008297:Male; D008727:Methotrexate / Q000633:toxicity; D015162:Micronucleus Tests; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D014750:Vincristine / Q000633:toxicity
chemical_list: D002699:Chlorambucil; D014750:Vincristine; D004317:Doxorubicin; D000165:Acridine Orange; D019813:1,2-Dimethylhydrazine; D008727:Methotrexate